A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs RO 7123520 (Primary) ; Methotrexate; Tumour necrosis factor alpha inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Roche
- 16 Mar 2017 Planned End Date changed from 1 Sep 2018 to 30 Sep 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 30 Sep 2018.
- 27 Dec 2016 New trial record